Journal of Clinical Medicine Article Antihypertensive Treatment in Kidney Transplant Recipients—A Current Single Center Experience Ulrich Jehn 1 , Katharina Schütte-Nütgen 1, Markus Strauss 2, Jan Kunert 1, Hermann Pavenstädt 1, Gerold Thölking 1 , Barbara Suwelack 1 and Stefan Reuter 1,* 1 Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, 48149 Münster, Germany;
[email protected] (U.J.);
[email protected] (K.S.-N.);
[email protected] (J.K.);
[email protected] (H.P.);
[email protected] (G.T.);
[email protected] (B.S.) 2 Department of Medicine C, Division of Cardiology and Angiology, University Hospital of Münster, 48149 Münster, Germany;
[email protected] * Correspondence:
[email protected]; Tel.: +49-251-83-47540; Fax: +49-251-83-56973 Received: 16 October 2020; Accepted: 3 December 2020; Published: 7 December 2020 Abstract: Arterial hypertension affects the survival of the kidney graft and the cardiovascular morbidity and mortality of the recipient after kidney transplantation (KTx). Thus, antihypertensive treatment is necessary for a vast majority of these patients. Long-term data on antihypertensive drugs and their effects on allograft function after KTx is still limited, and further investigation is required. We retrospectively analyzed a cohort of 854 recipients who received a kidney transplant at our transplant center between 2007 and 2015 with regard to antihypertensive treatment and its influence on graft function and survival. 1-y after KTx, 95.3% patients were treated with antihypertensive therapy. Of these, 38.6% received mono- or dual-drug therapy, 38.0% received three to four drugs and 8.1% were on a regimen of 5 drugs.